# Acasunlimab

Source: https://onco.cc/drugs/acasunlimab/  
OnCo record `acasunlimab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Acasunlimab is an experimental bispecific antibody from Genmab in phase 3 trials for non-small-cell lung cancer, aimed at PD-L1.

## Summary

Acasunlimab (GEN1046) is a bispecific antibody developed by Genmab. Its target is PD-L1 (the sponsor names PD-L1 x 4-1BB (CD137)). The sponsor states: Acasunlimab (GEN1046, DuoBody-PD-L1x4-1BB) is a bispecific antibody that co-targets PD-L1 and the costimulatory receptor 4-1BB, given intravenously in combination with pembrolizumab versus docetaxel in PD-L1-positive metastatic NSCLC that progressed after prior anti-PD-(L)1 therapy and chemotherapy. ClinicalTrials.gov describes the intervention as: Acasunlimab will be administered intravenously (IV). It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06635824 (Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)), in non-small-cell lung cancer. The largest, NCT06635824, plans to enrol 191 participants (actual) with primary completion expected 2027-07-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Also known as: DuoBody®-PD-L1×4-1BB
- Tags: pipeline; ctgov-ingest
- Code: GEN1046
- Modality: bispecific antibody
- Mechanism: Acasunlimab (GEN1046, DuoBody-PD-L1x4-1BB) is a bispecific antibody that co-targets PD-L1 and the costimulatory receptor 4-1BB, given intravenously in combination with pembrolizumab versus docetaxel in PD-L1-positive metastatic NSCLC that progressed after prior anti-PD-(L)1 therapy and chemotherapy.

## Sources

- ClinicalTrials.gov: trials of Acasunlimab: https://clinicaltrials.gov/search?intr=GEN1046

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [CD137 (4-1BB, TNFRSF9)](https://onco.cc/targets/cd137/), [PD-L1](https://onco.cc/targets/pdl1/)
- companies: [Genmab](https://onco.cc/companies/genmab/)
- trials: [Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer](https://onco.cc/trials/nct05117242/), [Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)](https://onco.cc/trials/nct06635824/)

---
JSON: https://onco.cc/api/v1/entities/acasunlimab.json